Is Penumbra, Inc. (PEN) a good stock to buy?

Olyth's institutional analysis of PEN reveals an Altman Z-Score of 21.47 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($1.40B most recent), help investors decide if PEN fits their risk profile.

What is the current P/E ratio for PEN?

As of the latest trading session, Penumbra, Inc. (PEN) has a trailing P/E ratio of 72.71.

Who is the CEO of Penumbra, Inc.?

The current Chief Executive Officer of Penumbra, Inc. is Adam Elsesser.

What was PEN's revenue for the last 5 years?

According to its latest income statements, Penumbra, Inc. reported annual revenues of $1.40B (2025), $1.19B (2024), $1.06B (2023), $0.85B (2022), $0.75B (2021) respectively.

Does PEN pay a dividend?

Penumbra, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does PEN have?

In its latest reporting period, Penumbra, Inc. generated $0.17B in Free Cash Flow against a total debt load of $0.22B.

What is the Price-to-Book (P/B) ratio of Penumbra, Inc.?

The Price-to-Book (P/B) ratio for Penumbra, Inc. (PEN) is currently 9.05.

What is the Price-to-Sales (P/S) ratio of PEN?

Based on trailing twelve-month data, Penumbra, Inc. (PEN) trades at a Price-to-Sales (P/S) ratio of 9.22.

What is Penumbra, Inc.'s Return on Equity (ROE)?

Penumbra, Inc. (PEN) has a Return on Equity (ROE) of 13.43%, representing its profitability relative to shareholder equity.

PEN

Penumbra, Inc. · Healthcare

329.68

0.06%(-0.19)

Market Open

Last Updated: — ET

52W L: $221.2652W H: $362.41

$329.64

CHG-8.30 (-2.46%)

H$343.75

L$225.43

VOL11M

PEN (1h)

Company Profile

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Sector

Healthcare

Industry

Medical - Devices

Employees

4,500

IPO Date

2015-09-18

Beta

0.84

Websitewww.penumbrainc.com↗

PEN

Penumbra (NYSE:PEN) Director Harpreet Grewal Sells 100 Shares

Penumbra (PEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Congress Asset Management Co. Trims Stake in Penumbra, Inc. $PEN

Penumbra, Inc. (NYSE:PEN) Given Average Rating of “Hold” by Brokerages

Penumbra (NYSE:PEN) & Lombard Medical (OTCMKTS:EVARF) Head-To-Head Survey